CBD and warfarin: INR risk, evidence, and monitoring

What the science says

The case evidence

Cortopassi 2020 is the most cited published case of a CBD-warfarin interaction: a patient on a stable warfarin dose added CBD and their INR rose to a clinically concerning level. This is consistent with what the pharmacokinetics predict — warfarin (specifically S-warfarin, the more potent enantiomer) is heavily CYP2C9-dependent, and CBD inhibits CYP2C9 competitively.

The pharmacokinetic evidence

Bansal 2023 (n=18 RCT) showed CBD raised CYP3A and CYP2C9 substrate plasma exposure 56–207% at research doses. The CYP2C9 inhibition by CBD was confirmed in vitro by Yamaori 2011. Stöllberger 2023's review of 403 CYP-substrate drugs flags warfarin as a high-priority interaction candidate, and Nachnani 2024's systematic review catalogs warfarin among the most consistently documented CBD drug interactions in the published literature.

Why warfarin is especially sensitive

Most drugs have enough pharmacokinetic buffer that modest CYP inhibition doesn't produce clinically significant effects. Warfarin doesn't. It has a narrow therapeutic window (target INR 2.0–3.0 for most indications; 2.5–3.5 for mechanical heart valves), and the difference between therapeutic anticoagulation and dangerous bleeding can be a single INR point. Any drug that affects CYP2C9 meaningfully — including CBD — demands monitoring when added to a warfarin regimen.

The mechanism

Warfarin exists as two enantiomers: S-warfarin (more pharmacologically active) is metabolized primarily by CYP2C9, while R-warfarin uses CYP1A2 and CYP3A4. CBD inhibits CYP2C9 competitively, slowing S-warfarin clearance and raising plasma levels. Higher warfarin plasma levels mean stronger anticoagulation and higher INR. The magnitude depends on:

• Your CYP2C9 genotype (poor metabolizers are already on the slow end; CBD inhibition has less room to move)
• Your warfarin dose and stability
• The CBD dose and format (oral > transdermal > topical for systemic CYP exposure)
• Other medications that also affect CYP2C9 (NSAIDs, fluconazole, amiodarone are common)

See the CYP450 mechanism explainer for the foundational pharmacology.

What this means for you

1. Tell your prescriber before starting CBD. This is the warfarin interaction with the clearest clinical case evidence. Your anticoagulation provider needs to know — and may want a baseline INR before you start.
2. Arrange more frequent INR monitoring. The first 2–4 weeks after initiating CBD (or changing dose) are the highest-risk window. More frequent checks let you catch a rising INR before it becomes a problem.
3. Dose conservatism matters. If your prescriber approves a CBD trial, start low — 10–15mg — and hold before titrating. See the titration protocol. Each dose change is effectively a new CYP2C9 inhibition event.
4. Consider the topical first. The NANO roll-on has minimal systemic absorption and negligible CYP2C9 impact. For localized joint or muscle use, it's the lowest-interaction-risk format.
5. Watch for bleeding signs. Unusual bruising, prolonged bleeding, blood in urine or stool, or heavy menstrual bleeding while on warfarin and CBD are signals to check INR and contact your prescriber immediately.
6. Don't stop warfarin independently. If you're concerned about the interaction, the conversation is with your prescriber — not a self-adjustment of your anticoagulant.

Warfarin brand names

Note: newer oral anticoagulants (DOACs) like apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) use different metabolic pathways. See the blood thinners overview for those interactions.